ABSTRACT
I. ABSTRACT The management of early breast cancer (EBC) is critical in defining the longterm outcome of the disease. This period is a window of opportunity that can allow us to manipulate micrometastatic tumor cells (if present) when they may be sensitive to endocrine therapy.
